Krish Patel, MD

Dr. Patel is a dual board-certified hematologist and medical oncologist at SCRI Oncology Partners and the director of lymphoma research at SCRI. Previously, he served as the Director of Hematologic Malignancies and Cell Therapy at the Swedish Cancer Institute in Seattle, Washington, where he led development of the program’s clinical standards for lymphoma care, assisted in the expansion of cell therapy services, and helped shape lymphoma research efforts. Dr. Patel was also a member of the Paul G. Allen Research Center at Seattle Cancer Institute, serving as a co-founding member of the Center for Immuno-oncology, where he collaborated on translational research related to immunotherapy in hematologic diseases.
His clinical and research interests are centered in the development of novel therapies for CLL and lymphomas and include early phase drug development and cellular therapy.
Dr. Patel has been published in various medical journals, including New England Journal of Medicine, Blood, and Journal of Clinical Oncology. He is also a member of the ASCO Cancer Communications Committee, the CIBMTR Lymphoma Working Committee, and the National Planning Committee for the Lymphoma Research Foundation Lymphoma Rounds.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaTopic:CLL/LymphomaDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AbbvieTopic:CLL/LymphomaDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BeiGeneTopic:CLL/LymphomaDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:CLL/Lymphoma/Cell TherapyDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:CaribouTopic:Cell TherapyDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:EpizymeTopic:LymphomaDate added:02/09/2023Date updated:09/16/2025Relationship end date:12/31/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Fate TherapeuticsTopic:Cell TherapyDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GenentechTopic:CLL/LymphomaDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:KiteTopic:Cell TherapyDate added:02/09/2023Date updated:09/16/2025
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Janssen/PharmacyclicsTopic:CLL/LymphomaDate added:02/09/2023Date updated:09/16/2025